<DOC>
	<DOCNO>NCT02669667</DOCNO>
	<brief_summary>This phase 1a randomize , blind , placebo-controlled , single-ascending dose study assess safety tolerability MEDI9314 healthy adult subject</brief_summary>
	<brief_title>Safety Tolerability MEDI9314 Single Ascending Dose Healthy Subjects</brief_title>
	<detailed_description>This phase I study assess safety , tolerability pharmacokinetics , immunogenicity MEDI9314 follow single dose administration healthy subject</detailed_description>
	<criteria>1 . Written informed consent . 2 . Age 18 50 year time screen . 3 . Female subject must nonchildbearing potential . 4 . Nonsterilized male sexually active female partner childbearing potential must use condom spermicide . 5 . Body mass index 19.0 32.0 kg/m2 screening . 6 . No clinically significant abnormality basis medical/medication history physical examination . 7 . Negative drug abuse ( DOA ) . 8 . Able willing comply requirement protocol complete study end safety follow period . 9 . For Japanese Cohort , subject 's parent set grandparent must Japanese . 1 . Any condition , opinion investigator , would interfere evaluation investigational product interpretation subject safety study result . 2 . Concurrent enrollment another clinical study involve treatment . 3 . Individuals legally institutionalize . 4 . Receipt &gt; 2 marketed investigational biologic agent . 5 . Receipt investigational biologic agent within 4 month 5 halflives prior screen , whichever longer . 6 . Receipt investigational non biologic agent within 3 month 5 half life prior screen , whichever longer . 7 . Use medication ( prescription counter , include herbal remedy ) within 14 day 5 half life Day 1 , whichever long , unless opinion investigator medical monitor medication interfere study procedure compromise subject safety . 8 . Known history allergy reaction component investigational product formulation . 9 . History anaphylaxis follow biologic therapy . 10 . Any clinically relevant abnormal finding physical examination ECG , vital sign , laboratory parameter . 11 . Positive tuberculosis ( TB ) test ( QuantiFERONÂ®TB Gold Intube ) . 12 . Positive hepatitis B surface antigen , hepatitis C virus antibody HIV test screening . 13 . Receipt live attenuate vaccine 30 day prior date screening . 14 . Where donation blood blood product excess 500 mL within 8week period 3 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MEDI9314</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>